Novavax announced expanded agreement with SK bioscience to manufacture COVID-19 vaccine with Omicron variant
On Jul. 19, 2022, Novavax announced that it had signed agreements with its partner, SK bioscience, for the manufacturing and supply of a version of the Novavax COVID-19 vaccine (NVX-CoV2373) containing Omicron variant and for the manufacture of the vaccine in prefilled syringes.
The companies signed an agreement for the technology transfer of Novavax’ proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants including the Omicron BA.5 subvariant.
In addition, the companies signed an agreement to manufacture and supply the Novavax COVID-19 vaccine in a prefilled syringe. SK bioscience began work to enable the manufacturing process for commercial supply of the vaccine in prefilled syringes in 2023.
Tags:
Source: Novavax
Credit: